三鑫医疗: 监事会决议公告

Meeting Overview - The 19th meeting of the 5th Supervisory Board of Jiangxi Sanxin Medical Technology Co., Ltd. was held on August 7, 2025, in compliance with relevant laws and regulations [1][2]. Financial Reporting - The Supervisory Board approved the company's 2025 semi-annual report, confirming that the report accurately reflects the company's actual situation without any false records or omissions [1][3]. Profit Distribution Plan - The company proposed a mid-term profit distribution plan, which includes a cash dividend of 1 yuan (including tax) for every 10 shares based on a total of 522,237,525 shares, after deducting 160,000 shares held in the repurchase account [2][3]. Stock Incentive Plan - The Supervisory Board approved the achievement of conditions for the first unlock period of the 2024 restricted stock incentive plan, allowing 112 eligible participants to unlock a total of 3,849,575 shares [3][4]. Convertible Bond Issuance - The company confirmed its eligibility to issue convertible bonds to unspecified investors, with a total fundraising target of up to 530 million yuan [5][6]. - The convertible bonds will be issued at face value, with a term of six years and an annual interest payment structure [6][7]. Fund Utilization - The proceeds from the bond issuance will be allocated to projects including the expansion of blood dialysis membrane production and the construction of high-performance blood purification equipment production lines, totaling 530 million yuan [17][18]. Governance and Compliance - The company established rules for the bondholders' meeting and outlined measures to mitigate the dilution of immediate returns for existing shareholders due to the bond issuance [21][22].